Publications & News

Stay Up-To-Date with Prolong

November 13, 2024

Prolong Pharmaceuticals to Present Clinical Data regarding PP-007, PEGylated carboxyhemoglobin bovine product, at the 2024 International Symposium on Blood Substitutes (ISBS)

Latest

October 30, 2024

U.S. Food and Drug Administration (FDA) Grants Prolong Pharmaceuticals FDA Fast Track Designation for Novel Stroke Therapy (PP-007) in HEMERA-1 Clinical Study

Positive HEMERA-1 data pave the way for further neuroprotection trials during ‘thrombectomy era’

HEMERA‐1 CarboxyHEMoglobin OxygEn Delivery for Evascularization in Acute Stroke: A Prospective, Randomized Phase 1 Clinical Trial

October 1, 2023

Measuring And Controlling Potency Of A Targetless Biologic: Study Of Pegylated Hemoglobin

All our resources

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

December 1, 2017

Prolong Pharmaceuticals Announces Completion of Enrollment in Phase II Study of SANGUINATE® in the Treatment of Sickle Cell Disease Patients with Vaso-Occlusive Crisis in an Ambulatory Setting

October 1, 2017

Sanguinate: A Novel Blood Substitute Product

Pegylated bovine carboxyhaemoglobin utilisation in a thrombotic thrombocytopenic purpura patient

Sickle Cell Disease: Treatment and Management

Summary of the Interagency Oxygen Carrier State of the Science Meeting

Hemoglobin-Based Oxygen Carriers: An Update

SANGUINATE (PEGylated Carboxyhemoglobin Bovine): Mechanism of Action and Clinical Update.

Blood Replacement ‘A Bridge to Life’ for Upstate Man

Comparison of the Pharmacokinetic Properties of Hemoglobin-Based Oxygen Carriers

REVIEW

April 1, 2017

41(4): 346-350. Abuchowski A.

SANGUINATE (PEGylated Carboxyhemoglobin Bovine): Mechanism of Action and Clinical Update. Artif Organs.

SCD

March 1, 2017

39(1):20-27 | Misra H, Bainbridge J, Berryman J, Abuchowski A, Galvez KM, Uribe LF, Hernandez AL, Sosa NR.

A Phase Ib open label, randomized, safety study of SANGUINATE® in patients with sickle cell anemia. Rev Bras Hematol Hemoter.

BNAO

February 1, 2017

29: 73-80 | Thenuwara K, Thomas J, Ibsen M, Ituk U, Choi K, Nickel E, Goodheart MJ.

Use of hyperbaric oxygen therapy and PEGylated carboxyhemoglobin bovine in a Jehovah's Witness with life-threatening anemia following postpartum hemorrhage. Int J Obstet Anesth.

Learn how you can be part of the journey

Join us in revolutionizing treatments for severe
and life-threatening conditions

or